Menu Menu

What is Living Evidence?

Living Evidence uses continuous evidence surveillance and rapid response pathways to incorporate new relevant evidence into systematic reviews and clinical practice guideline recommendations as soon as it becomes available.

Practically, this means that living systematic reviews and living guidelines:

  • Are underpinned by continual, active evidence surveillance and monitoring.
  • Rapidly incorporate new important evidence that is identified.
  • Can communicate in near real-time the current status of the review or guideline, and any new evidence being incorporated in the recommendation/s.

In addition to continuous updating, Living Evidence aims to improve the quality, use and value of evidence synthesis activities by:

  • Engaging large and diverse groups of stakeholders to be actively engaged in finding and appraising evidence.
  • Broadening the range of research and health-related data that can be included, such as real-world data from clinical quality registries and individual patient-level data.
  • Publishing recommendations in multi-layered digitals formats that can be integrated at the point of care into electronic medical records and decision support tools.
  • Using structured (semantic) data to improve the discoverability and re-use of research and health-related data.
Slide 9
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 18
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 2
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 3
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 4
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 5
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 6
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 7
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 8
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 10
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 1
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 11
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 12
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 13
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 14
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 15
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 16
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
Slide 17
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.

Our approach to recommendation development

The Collaboration uses a world-leading Living Evidence approach, which combines rigorous, evidence-based methods and rapid updating. This enables us to modify and update recommendations rapidly in response to the publication of new research evidence.

The guidelines use the GRADE methods and are designed to meet Australian NHMRC standards.

Relevant new questions to be addressed are continually sought from stakeholders and practitioners. For prioritised questions, the evidence is actively monitored and updated. Evidence surveillance combines horizon scans and targeted searches.

An evidence team appraises and synthesises evidence and prepares evidence-to-decision frameworks to inform development of recommendations by multidisciplinary clinical panels.

A guidelines leadership group oversees the development of recommendations by these expert panels and is advised by a consumer panel.

After initial approval by the Guidelines Leadership Group, all recommendations require 100% consensus by our 35 member organisations.

Endorsed recommendations are published online in MAGICapp and disseminated through traditional and social media channels.

Recommendation development and approval process

  1. Literature searches (Daily, weekly or monthly as required)
  2. Publications screened, included studies appraised, Evidence Profile and Summary of Findings tables developed or added to (as required)
  3. Guideline Panels (clinical and consumer) consider new evidence and draft guidance – recommendations and Flowcharts (as required)
  4. Guideline Leadership Group reviews all draft recommendations from Expert Clinical Panels, and approves for submission to Steering Committee (as required) 
  5. Steering Committee reviews and approves new and updated recommendations for publication (as required)

More information

Condition-specific methods and processes

CASE STUDY: LIVING EVIDENCE IN ACTION

THE NATIONAL CLINICAL EVIDENCE TASKFORCE

The global response to the COVID-19 pandemic highlighted the many ways a shared sense of urgency can break down traditional barriers to innovation and collaboration, and deliver extraordinary results. Here in Australia, the National Clinical Evidence Taskforce harnessed collective commitment and multi-disciplinary expertise to deliver the world-first infrastructure, networks and know-how to deliver living clinical guidelines. As a result, clinicians were equipped with near-real time, trusted evidence in crisis conditions.

The Taskforce demonstrated that partnerships are a foundational element of living evidence production, drawing on national professional, research and consumer groups and global organisations including WHO, NICE, Cochrane Canada and the Danish Health Authority.

The resulting infrastructure, processes and genuinely collaborative model that emerged enabled 200+ contributors from 35 national peak health bodies representing all major clinical groups to deliver the trusted evidence Australians urgently needed each week over the past three years.

Together, the Taskforce’s 15 expert panels developed 23 clinical flowcharts and updated the national COVID-19 clinical guidelines over 100 times with more than 200 recommendations. Clinical scope expanded over time to include guidance for the care of children, adolescents, adults, pregnant or breastfeeding women, and older people – highlighting the viability, impact and value of living evidence now and into the future.

To find out more about the impact of the Taskforce visit at evidenceinaction.org/

Slide 1
How we develop
Living Recommendations
National Clinical Evidence Taskforce logo
The Taskforce explainer infographic cannot be viewed on mobile.
Please come back and experience on tablet or larger.
COVID-19 Pandemic:
Questions need answers
In the course of separating fact from
fiction, at no time in recent history
has the need to explore the effects
of interventions on a new disease
like COVID-19 been more critical.
To develop clear recommendations
about what we know and what we
don’t know, we have established a
multi-disciplinary collaboration
between researchers and clinicians
to provide evidence-based,
trustworthy guidance for the
treatment of people with COVID-19.
Join the dots as we step
through the process
Blue signifies the work of the
Taskforce Evidence Team
Pink signifies the
contributions
of the Taskforce Expert
Panels and Groups
Slide 2
The process is simple:
We start with a question
This can be broad or specific. It can be
proposed by clinicians, members of the
public and/or government agencies.
Example questions:
Clinicians
Consumers & carers
Policy makers
Question prioritisation
Guidelines
Leadership Group
Firstly, the question posed
is assessed by the
Guidelines Leadership
Group to make sure that it
is in scope.
Slide 3
The Taskforce gets busy:
Finding evidence
Patient or population:
What are the important characteristics?
Intervention:
What treatment is being considered?
Comparison:
What is it being compared to?
Outcome:
What benefits or harms does it cause?
PICO
The acronym used to
help formulate a well-defined
searchable question
Searching
Globally, around 1000 studies are published
every week that explore treatments for
COVID-19. The role of the Evidence Team is to
sift through these publications to identify the
most reliable studies that will guide treatment
recommendations.
Global COVID-19 Literature
Relevant high quality research
Relevant low quality research
Irrelevant research literature
The Evidence Team
The engine room of the Taskforce.
The team of methodologists and evidence
officers works with the panels to define questions
for systematic review, undertake literature
searches and use GRADE methods to critically
appraise and present relevant findings.
Slide 4
Panels dive in to the
Assess the evidence
Conflicts of Interest Committee
An international and independent
committee responsible for assessing the
Declarations of Conflicts of Interest
completed by Taskforce contributors.
Expert Advisory Group
Comprised of professionals with specific expertise
that can be called upon as required by the Evidence
Team and panels to help guide recommendations.
Expert Clinical Panels
Senior healthcare professionals with relevant
clinical expertise and an understanding of the
principles of evidence-based practice.
Consumer Panel
Co-convened with the Consumers Health Forum of Australia, this
panel provides consumer advice to the guideline development
program, contributing ideas for clinical questions to be addressed,
views on high priority topics, and feedback on the implications
of individual recommendations to patients, consumers, or carers.
GRADE Assessment
Bias
Consistency
Precision
Applicability
Slide 6
Expert panels develop:
Proposed recommendation
Corticosteroids for adults:
Use dexamethasone 6 mg daily intraveneously or orally for up to 10 days (or acceptable alternative regimen) in adults with COVID-19 who are receiving oxygen (including mechanically ventilated patients).
The Evidence Team prepare a summary of the evidence to accompany the recommendation.
Decision time:
Recommended approval
If the GLG requires changes, the draft recommendation goes back to the relelvant Guidelines panel for further development.
Guidelines Leadership Group
Provides clinical governance to the Taskforce and comprises the chairs from each of the Expert Clinical Panels, consumer representatives, and a senior clinical representative nominated by each of the Taskforce member organisations. The GLG is responsible for reviewing all new or updated recommendations drafted by the Panels before they are submitted to the Steering Committee for final approval.
Slide 7
With 100% consensus we deliver a
Published recommendation
Jurisdictional Liaison Group
Includes representatives from Federal and State health
departments and other government agencies as appro-
priate. Primarily a communication channel to ensure
mutual awareness of evidence surveillance and pub-
lished clinical guidance, with the key role of ensuring
early identification of implementation issues associat-
ed with specific recommendations and to help guide
priority questions.
National Steering Committee
Governed by a 100% consensus-based
decision-making process and comprising a
representative from each of the member
organisations. Approval is considered to be a formal
endorsement of the guidelines by all members.
Published recommendation
Once the Steering Committee has
approved the recommendations,
the Guidelines are published and
dissemination begins.
Slide 8
Guidelines dissemination
Once approved, the latest Guidelines are
published to the online platform MAGICapp and
the Taskforce website is updated. A summary
Communique is sent to subscribers, media and
the 35 member organisations for distribution
through their channels. Social media is
also used to promote publication and receive
feedback on the guidelines.
Slide 9
Updating and maintenance
Living recommendations are published and
updated as relevant evidence emerges. This means
our 200+ published recommendations are rapidly
reviewed as new results are identified and then
incorporated into the recommendation’s body of
evidence to determine whether an update is
required. It’s a constant cycle of identify, review,
develop, approve, publish, disseminate.
Slide 10
200+
volunteer clinical experts
28,000+
volunteer hours
15+
Taskforce Project Team
200
countries
24,000+
studies
screened
715,000+
guideline
users
100+
updates
200+
living
recommendations
23
clinical
flowcharts
National Clinical Evidence Taskforce logo
@evidence_aus
wwww.clinicalevidence.net.au
© 2021 National COVID-19 Clinical Evidence Taskforce. All rights reserved.